F&G Annuities & Life ( FG ) declares $0.25/share quarterly dividend , in line with previous. Forward yield 3.39% Payable June 30; for shareholders of record June 16; ex-div June 16. See FG Dividend Scorecard, Yield Chart, & Dividend Growth. More on F&G Annuities & Life F&G Annuities & Life: Addressing Market Fears Over Its Private Credit Exposure F&G Annuities & Life, Inc. (FG) Q4 2025 Earnings Ca...
F&G Annuities & Life ( FG ) declares $0.25/share quarterly dividend , in line with previous. Forward yield 3.39% Payable June 30; for shareholders of record June 16; ex-div June 16. See FG Dividend Scorecard, Yield Chart, & Dividend Growth. More on F&G Annuities & Life F&G Annuities & Life: Addressing Market Fears Over Its Private Credit Exposure F&G Annuities & Life, Inc. (FG) Q4 2025 Earnings Call Transcript F&G Annuities & Life, Inc. 2025 Q4 - Results - Earnings Call Presentation Third Avenue Real Estate Value Fund adds BKD, HNLGY; exits FG, RYN among Q1 moves F&G Annuities & Life authorizes $100 million share repurchase program
Griffon press release ( GFF ): Q2 Non-GAAP EPS of $1.05 beats by $0.06 . Revenue of $421.9M (-1.1% Y/Y) beats by $7.31M . Adjusted EBITDA from continuing operations for the second quarter was $97.8 million, a 4% decrease from the prior year quarter of $101.7 million. 2026 Outlook Griffon's fiscal year 2026 outlook is unchanged from the first quarter, and is consistent with the expected contributio...
Griffon press release ( GFF ): Q2 Non-GAAP EPS of $1.05 beats by $0.06 . Revenue of $421.9M (-1.1% Y/Y) beats by $7.31M . Adjusted EBITDA from continuing operations for the second quarter was $97.8 million, a 4% decrease from the prior year quarter of $101.7 million. 2026 Outlook Griffon's fiscal year 2026 outlook is unchanged from the first quarter, and is consistent with the expected contributions from the legacy HBP segment and Hunter Fan as included within Griffon’s guidance provided in November 2025. Griffon expects fiscal 2026 revenue from continuing operations to be $1.8 billion vs. consensus of $2.00B . Adjusted EBITDA, presented to reflect Griffon's new reporting structure, is expected to be $458 million, excluding certain charges that affect comparability. Free cash flow from continuing operations, including capital expenditures of $50 million, is expected to exceed net income from continuing operations, with depreciation of $27 million and amortization of $15 million. Fiscal year 2026 interest expense is expected to be $93 million, excluding any interest income from the anticipated AMES joint venture. Griffon’s normalized tax rate is expected to be 28%. More on Griffon Griffon Remains A Good Play Even After Skyrocketing Griffon Corporation 2026 Q1 - Results - Earnings Call Presentation Griffon Q2 2026 Earnings Preview Seeking Alpha’s Quant Rating on Griffon Historical earnings data for Griffon
DUBAI, United Arab Emirates, May 07, 2026 (GLOBE NEWSWIRE) -- Halper AI has won the 2026 Global Recognition Award — selected from a field of over 15,000 applicants and evaluated alongside NVIDIA and Neuralink using the Rasch psychometric measurement model. Scoring at the highest levels across Innovation, Leadership, Service, and AI and Research, the award confirms what Halper's users have been say...
DUBAI, United Arab Emirates, May 07, 2026 (GLOBE NEWSWIRE) -- Halper AI has won the 2026 Global Recognition Award — selected from a field of over 15,000 applicants and evaluated alongside NVIDIA and Neuralink using the Rasch psychometric measurement model. Scoring at the highest levels across Innovation, Leadership, Service, and AI and Research, the award confirms what Halper's users have been saying for months: the product works. And now Halper AI is announcing its expansion into healthcare as
4kodiak/iStock Unreleased via Getty Images Amazon ( AMZN ) announced on Thursday that Novo Nordisk’s ( NVO ) newly launched oral diabetes therapy, the Ozempic pill, will be available for same-day delivery through its pharmacy division and dispensed at its One Medical locations via in-office kiosks. The Danish drugmaker launched the Ozempic pill earlier this week, having rebranded its previous oral...
4kodiak/iStock Unreleased via Getty Images Amazon ( AMZN ) announced on Thursday that Novo Nordisk’s ( NVO ) newly launched oral diabetes therapy, the Ozempic pill, will be available for same-day delivery through its pharmacy division and dispensed at its One Medical locations via in-office kiosks. The Danish drugmaker launched the Ozempic pill earlier this week, having rebranded its previous oral GLP-1 therapy, Rybelsus. Amazon ( AMZN ) stated that, regardless of Prime membership, patients will be able to access the once-daily therapy through same-day delivery, which is available in nearly 3,000 U.S. cities and towns. The company plans to expand the same-day service to nearly 4,500 cities and towns by the end of 2026. Additionally, the Ozempic pill will soon be available at in-office kiosks located at some of its One Medical primary care clinics for dispensing within minutes after medical appointments, Amazon ( AMZN ) said, adding that the initiative allows patients to avoid long pharmacy lines. Pricing for patients with insurance starts at $25 per month, while cash-paying customers can buy the starting dose of the Ozempic pill for $149 per month. More on Amazon, Novo Nordisk A/S Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It Novo Nordisk: Misread Q1 Earnings, Mispriced Stock Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline
4kodiak/iStock Unreleased via Getty Images Amazon ( AMZN ) announced on Thursday that Novo Nordisk’s ( NVO ) newly launched oral diabetes therapy, the Ozempic pill, will be available for same-day delivery through its pharmacy division and dispensed at its One Medical locations via in-office kiosks. The Danish drugmaker launched the Ozempic pill earlier this week, having rebranded its previous oral...
4kodiak/iStock Unreleased via Getty Images Amazon ( AMZN ) announced on Thursday that Novo Nordisk’s ( NVO ) newly launched oral diabetes therapy, the Ozempic pill, will be available for same-day delivery through its pharmacy division and dispensed at its One Medical locations via in-office kiosks. The Danish drugmaker launched the Ozempic pill earlier this week, having rebranded its previous oral GLP-1 therapy, Rybelsus. Amazon ( AMZN ) stated that, regardless of Prime membership, patients will be able to access the once-daily therapy through same-day delivery, which is available in nearly 3,000 U.S. cities and towns. The company plans to expand the same-day service to nearly 4,500 cities and towns by the end of 2026. Additionally, the Ozempic pill will soon be available at in-office kiosks located at some of its One Medical primary care clinics for dispensing within minutes after medical appointments, Amazon ( AMZN ) said, adding that the initiative allows patients to avoid long pharmacy lines. Pricing for patients with insurance starts at $25 per month, while cash-paying customers can buy the starting dose of the Ozempic pill for $149 per month. More on Amazon, Novo Nordisk A/S Novo Nordisk: Mixed Q1 Does Not Break The Thesis, But Also Does Not Strengthen It Novo Nordisk: Misread Q1 Earnings, Mispriced Stock Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript Novo Nordisk actively seeking deals to expand pipeline, CEO says Novo Nordisk says oral Wegovy success to soften sales decline
Cars.com press release ( CARS ): Q1 Non-GAAP EPS of $0.45 misses by $0.01 . Revenue of $180.2M (+0.7% Y/Y) in-line. Adjusted EBITDA grew to $51.0 million, up 1% year-over-year; Adjusted EBITDA margin of 28.3% outperformed guidance of 26% to 27% Net cash provided by operating activities was $39.8 million compared to $29.5 million in the prior year Share repurchases totaled 3.8 million shares for $3...
Cars.com press release ( CARS ): Q1 Non-GAAP EPS of $0.45 misses by $0.01 . Revenue of $180.2M (+0.7% Y/Y) in-line. Adjusted EBITDA grew to $51.0 million, up 1% year-over-year; Adjusted EBITDA margin of 28.3% outperformed guidance of 26% to 27% Net cash provided by operating activities was $39.8 million compared to $29.5 million in the prior year Share repurchases totaled 3.8 million shares for $33 million through April 30, 2026; 2026 repurchase target has been increased to $90 million. Outlook Second Quarter 2026 Revenue is expected to be flat to up 2% year-over-year vs. estimated growth of 1.25% Y/Y , driven by continued Dealer revenue growth. OEM and National revenue is expected to remain under pressure, and guidance assumes that current advertising spending trends remain consistent for the quarter. Adjusted EBITDA margin is expected to be between 28.0% and 29.0%, reflecting operating efficiencies and a partial quarter of cost savings benefit from the cost reduction program undertaken in April. Full Year 2026 The Company reaffirms its full year 2026 guidance: Revenue is expected to be flat to up 2% year-over-year vs. estimated growth of 1.16% Y/Y. Adjusted EBITDA margin is expected to be between 29.0% to 30.0% More on Cars.com Cars.com: A Struggling Business As Consumer Traffic Declines Cars.com Inc. (CARS) Q4 2025 Earnings Call Transcript Cars.com Inc. 2025 Q4 - Results - Earnings Call Presentation Cars.com Q1 2026 Earnings Preview Cars.com accelerates AI push, cuts costs, boosts buyback plan
Richard Drury Foreign healthcare stocks are earning some of the market's strongest Quant conviction right now, with the top five names on this ranking all carrying scores above 4.19, a cluster of high-conviction signals spanning Ireland, the UK, Japan, Sweden, and the UK again, reflecting how broadly the Quant system is rewarding international pharma and biotech on valuation, momentum, and profita...
Richard Drury Foreign healthcare stocks are earning some of the market's strongest Quant conviction right now, with the top five names on this ranking all carrying scores above 4.19, a cluster of high-conviction signals spanning Ireland, the UK, Japan, Sweden, and the UK again, reflecting how broadly the Quant system is rewarding international pharma and biotech on valuation, momentum, and profitability metrics. Below is a list of the top 10 foreign healthcare stocks ranked according to their Seeking Alpha Quant Ratings. This list focuses on non-domestic healthcare companies across various sectors including pharmaceuticals, biotechnology, and health care equipment. Jazz Pharmaceuticals ( JAZZ ) leads the list with a 4.86 Quant score, standing out as one of the highest-rated specialty pharma names globally on the back of a diversified neuroscience and oncology portfolio. AstraZeneca ( AZN ) follows at 4.75, a result that reflects both the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma names globally that the Quant system currently views favorably. Japanese pharma Astellas ( ALPMY ), notably flagged as a Strong Buy by the Quant system ahead of Q1 earnings season, and rare disease specialist Swedish Orphan Biovitrum ( SWOBY ) round out the top four, together making the case that foreign healthcare's Quant story is as much about specialty and orphan drug pipelines as it is about traditional large-cap pharma dominance. The bottom half of the list, where Sandoz ( SDZNY ) and Galderma ( GALDY ) both sit just below the 3.5 bullish threshold at 3.35, serves as a reminder that not all foreign healthcare names are receiving equal treatment from the Quant system. Here is the list: Jazz Pharmaceuticals plc ( JAZZ ), Quant Rating: 4.86 AstraZeneca PLC ( AZN ), Quant Rating: 4.75 Astellas Pharma Inc. ( ALPMY ), Quant Rating: 4.64 Swedish Orphan Biovitrum AB (publ) ( SWOBY ), Quant Rating: 4.63 LivaNova PLC ( LIVN ), Quant Rating: 4.19 Ro...
Harmony Biosciences Holdings, Inc. press release ( HRMY ): Q1 GAAP EPS of $0.55 misses by $0.14 . Revenue of $215.3M (+16.6% Y/Y) misses by $5.54M . General and Administrative expenses were $32.5 million in the first quarter of 2026, as compared to $31.2 million for the same quarter in 2025, representing a 4% increase Total Operating Expenses were $133.6 million in the first quarter of 2026, as co...
Harmony Biosciences Holdings, Inc. press release ( HRMY ): Q1 GAAP EPS of $0.55 misses by $0.14 . Revenue of $215.3M (+16.6% Y/Y) misses by $5.54M . General and Administrative expenses were $32.5 million in the first quarter of 2026, as compared to $31.2 million for the same quarter in 2025, representing a 4% increase Total Operating Expenses were $133.6 million in the first quarter of 2026, as compared to $96.5 million for the same quarter in 2025, representing a 38% increase More on Harmony Biosciences Holdings, Inc. Harmony Biosciences: Four More Wakix Years, Nothing Visible Beyond Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript Harmony Bio spikes after new Wakix patent litigation Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline
Kelly Services press release ( KELYA ): Q1 Non-GAAP EPS of $0.03 misses by $0.03 . Revenue of $1B (-13.8% Y/Y) misses by $20M . More on Kelly Services Kelly Services: The Stock Nobody's Talking About Kelly Services, Inc. (KELYA) Q4 2025 Earnings Call Transcript Kelly Services, Inc. 2025 Q4 - Results - Earnings Call Presentation Kelly Services outlines mid-single-digit revenue decline for 2026 as t...
Kelly Services press release ( KELYA ): Q1 Non-GAAP EPS of $0.03 misses by $0.03 . Revenue of $1B (-13.8% Y/Y) misses by $20M . More on Kelly Services Kelly Services: The Stock Nobody's Talking About Kelly Services, Inc. (KELYA) Q4 2025 Earnings Call Transcript Kelly Services, Inc. 2025 Q4 - Results - Earnings Call Presentation Kelly Services outlines mid-single-digit revenue decline for 2026 as technology modernization and AI integration accelerate Kelly Services Non-GAAP EPS of $0.16 misses by $0.27, revenue of $1.05B beats by $20M
Jonathan Kitchen Global equities have remained resilient despite escalating tensions in the Middle East, with strong corporate earnings continuing to underpin the rally, according to Capital.com senior market analyst Kyle Rodda in an interview with Seeking Alpha. “The markets are pricing in the best-case scenario when it comes to the war,” Rodda said, warning that such optimism “could prove to be ...
Jonathan Kitchen Global equities have remained resilient despite escalating tensions in the Middle East, with strong corporate earnings continuing to underpin the rally, according to Capital.com senior market analyst Kyle Rodda in an interview with Seeking Alpha. “The markets are pricing in the best-case scenario when it comes to the war,” Rodda said, warning that such optimism “could prove to be a fatal conceit.” The comments come as investors track the Iran situation, where tensions have raised concerns over potential disruptions in the Strait of Hormuz, a key chokepoint for global oil flows. While there have been intermittent signs of de-escalation, the risk of supply disruptions remains, keeping energy markets volatile and markets sensitive to further headlines. Rodda said the strength in equities is primarily earnings-driven. First-quarter earnings growth of 27% has significantly outpaced the 13% consensus estimate heading into the reporting season. “The main driver of this rally is Wall Street’s remarkable earnings growth,” he said. The Federal Reserve, meanwhile, has taken a back seat in the current market narrative. The central bank kept interest rates unchanged at its latest meeting and signaled it would look through energy-driven inflation pressures for now, even as uncertainty around the outlook persists. “It’s a small part,” Rodda said, referring to the Fed’s role, noting that markets have continued to reach record highs despite policy ambiguity. Oil remains the key risk to equities. Rodda said Brent crude above $130 per barrel would pose a significant challenge, particularly if price gains are sharp and sustained. “Higher, faster, and longer is the worst-case scenario,” he said. If geopolitical tensions intensify and energy prices remain elevated, Rodda warned U.S. equities could enter a bear market, falling 20%–25% over the next six to 12 months. More on markets The U.S.-Iran Hormuz Deal: Last Chance To Prevent Oil Spike To $200 This Market Looks Like ...